Skip to main content

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter?s Syndrome

Clinical Trial Grant
Duke Scholars

Awarded By

Genmab US, Inc.

Start Date

December 19, 2023

End Date

December 30, 2028
 

Awarded By

Genmab US, Inc.

Start Date

December 19, 2023

End Date

December 30, 2028